共 62 条
[1]
Appell R.A.(1997)Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis Urology 50 90-6
[2]
Abrams P.(1998)Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder Br J Urol 81 801-10
[3]
Freeman R.(1999)Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 10 283-9
[4]
Anderström C.(2000)Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms Clin Drug Invest 19 83-91
[5]
Drutz H.(2000)The mechanism of action of tolterodine Rev Contemp Pharmacother 11 13-27
[6]
Appell R.A.(1998)Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes Drug Metab Dispos 26 289-93
[7]
Gleason D.(1977)Polymorphic hydroxylation of debrisoquine in man Lancet II 584-6
[8]
Chancellor M.(1990)Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations Eur J Clin Pharmacol 39 533-7
[9]
Freedman S.(1998)Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine Clin Pharmacol Ther 63 529-39
[10]
Mitcheson H.D.(1999)Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data Urology 53 990-8